Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials

被引：0

作者：

Silverberg, Jonathan ^{[1
]}

Thaci, Diamant ^{[2
]}

Seneschal, Julien ^{[3
,4
]}

Gold, Linda Stein ^{[5
]}

Blauvelt, Andrew ^{[6
]}

Simpson, Eric ^{[7
]}

Chu, Chia-Yu ^{[8
,9
]}

Liu, Zhuqing ^{[10
]}

Lima, Renata Gontijo ^{[10
]}

Pillai, Sreekumar ^{[10
]}

Guttman-Yassky, Emma ^{[11
]}

机构：

[1] George Washington Univ, Sch Med, Washington, DC USA

[2] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[3] Univ Bordeaux, Bordeaux, France

[4] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Bordeaux, France

[5] Henry Ford Hlth Syst, Detroit, MI USA

[6] Oregon Med Res Ctr, Portland, OR USA

[7] Oregon Hlth & Sci Univ, Portland, OR USA

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[10] Eli Lilly & Co, Indianapolis, IN USA

[11] Icahn Sch Med Mt Sinai, New York, NY USA

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P075

引用

页码：62 / 62

页数：1

共 50 条

[1] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials
Silverberg, Jonathan I.
Thaci, Diamant
Seneschal, Julien
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Guttman-Yassky, Emma
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E97 - E98
[2] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Gil, Esther Garcia
Silverberg, Jonathan, I
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 740 - 748
[3] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
Marquardt, Tzvetelina
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
[4] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Carrascosa, Jose Manuel
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan, I
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[5] LEBRIKIZUMAB IMPROVES PATIENT-REPORTED SYMPTOMS OF ANXIETY AND DEPRESSION IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM THREE RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 3 TRIALS
Lio, Peter
Armstrong, April
Guenthner, Scott
Gutermuth, Jan
Zhong, Jinglin
Pierce, Evangeline
Dawson, Zach
Witte, Michael
Thyssen, Jacob P.
Wollenberg, Andreas
ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 31 - 31
[6] Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5)
Simpson, E.
Forman, S.
Silverberg, J.
Zirwas, M.
Maverakis, E.
Han, G.
Guttman-Yassky, E.
Marnell, D.
Bissonnette, R.
Waibel, J.
Nunes, F.
DeLozier, A.
Angle, R.
Holzwarth, K.
Goldblum, O.
Zhong, J.
Papp, K.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E97
[7] Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Silverberg, Jonathan I.
Guttman-Yassky, Emma
Thaci, Diamant
Irvine, Alan D.
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric L.
Chu, Chia-Yu
Liu, Zhuqing
Lima, Renata Gontijo
Pillai, Sreekumar G.
Seneschal, Julien
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (12): : 1080 - 1091
[8] Lebrikizumab in combination with topical corticosteroids improves quality of life in patients with moderate-to-severe atopic dermatitis: results from a phase III randomized, double-blinded, placebo-controlled trial (ADhere)
Forman, Seth
Gutermuth, Jan
de Bruin-Weller, Marjolein
Moore, Angela
Guenthner, Scott
Wolf, Eric
Pierce, Evangeline
Witte, Michael M.
Zhong, Jinglin
Wollenberg, Andreas
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E109
[9] Lebrikizumab treatment improves quality of life in patients with moderate-to-severe atopic dermatitis: results from two phase III randomized, double-blinded, placebo-controlled trials (ADvocate1 and ADvocate2)
Lio, Peter
Armstrong, April
Gutermuth, Jan
Nosbaum, Audrey
Sofen, Howard
Casillas, Marta
Pierce, Evangeline
Elmaraghy, Hany
Chen, Sherry
Thyssen, Jacob P.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E110
[10] Efficacy and Safety of Lebrikizumab in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3, Randomized, Placebo-Controlled Trial (ADhere)
Simpson, Eric L.
Gooderham, Melinda
Wollenberg, Andreas
Weidinger, Stephan
Armstrong, April
Soung, Jennifer
Ferrucci, Silvia
Lima, Renata Gontijo
Xu, Wen
Witte, Michael M.
Blauvelt, Andrew
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 61

← 1 2 3 4 5 →